Dj 1 (Park7) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
DJ-1, encoded by the PARK7 gene on chromosome 1p36.23, is a highly conserved 189-amino acid protein that functions as a multifunctional [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- sensor, molecular chaperone, and glyoxalase. Homozygous or compound heterozygous loss-of-function mutations in PARK7 cause autosomal recessive early-onset [Parkinson's Disease (PD)[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, first identified by [Bonifati et al. (2003)(https://pubmed.ncbi.nlm.nih.gov/12446870/). DJ-1 mutations account for approximately 1–2% of autosomal recessive early-onset PD cases (Lockhart et al., 2004) (Lockhart et al., 2004).
DJ-1 is ubiquitously expressed in human tissues with particularly high expression in the brain, including dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- of the [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, and [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia; Honbou et al., 2003)) (Wilson et al., 2003).
Key structural features include:
-
Cysteine 106 (C106): The most critical residue for DJ-1 function, located in a "nucleophile elbow" pocket. C106 is exquisitely sensitive to oxidation, transitioning from thiol (-SH) to sulfinic acid (-SO₂H) under mild oxidative stress and to sulfonic acid (-SO₃H) under severe stress. The sulfinic acid form represents the "activated" state of DJ-1 and is essential for its neuroprotective functions (Canet-Avilés et al., 2004). Over-oxidation to sulfonic acid inactivates the protein.
-
Homodimer interface: DJ-1 functions as an obligate homodimer, with the dimer interface mediated primarily by helices α1, α7, and the β-strand β5. [Disease-causing mutations such as L166P and M26I destabilize the dimer, leading to protein instability and degradation (Olzmann et al., 2004).
-
Catalytic triad: The residues Cys106, His126, and Glu18 form a putative catalytic triad that mediates DJ-1's enzymatic activities.
DJ-1 is a dedicated oxidative stress sensor and antioxidant protein (Taira et al., 2004) (Singh et al., 2025):
- [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- Scavenging: DJ-1 directly quenches [reactive oxygen species (ROS)[/entities/[ros[/entities/[ros[/entities/[ros--TEMP--/entities)--FIX-- through oxidation of its C106 residue. Oxidized DJ-1 translocates from the cytoplasm to [mitochondria], where it protects against oxidative damage.
- Transcriptional Regulation: DJ-1 stabilizes the antioxidant transcription factor [Nrf2[/proteins/[nrf2[/proteins/[nrf2[/proteins/[nrf2--TEMP--/proteins)--FIX-- by preventing its interaction with Keap1, promoting expression of antioxidant [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes including heme oxygenase-1, glutathione S-transferase, and [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX-- target genes (Clements et al., 2006).
- ASK1 Inhibition: DJ-1 suppresses [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX-- signal-regulating kinase 1 (ASK1), a MAP kinase kinase kinase that activates cell death pathways under oxidative stress.
DJ-1 functions as a glutathione-independent glyoxalase that detoxifies methylglyoxal (MGO), a highly reactive glycolytic byproduct that damages [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins through glycation (Lee et al., 2012). Recent biochemical studies clarified that DJ-1 catalyzes the stereospecific conversion of MGO to D-lactate and glycolate, which support mitochondrial membrane potential (Andreeva et al., 2024). While DJ-1 was initially proposed to be a protein deglycase, subsequent kinetic analyses demonstrated that the apparent deglycation activity arises from DJ-1's glyoxalase function acting on the equilibrium between free MGO and its protein adducts (Pfaff et al., 2024) (Pfaff et al., 2024).
Additionally, DJ-1 functions as an efficient hydrolase of cyclic 3-phosphoglyceric anhydride (cPGA), protecting proteins from acylation (Trentini et al., 2024) (Andreeva et al., 2024).
DJ-1 localizes to [mitochondria], where it plays critical protective roles:
- Complex I maintenance: DJ-1 directly binds to NDUFA4 and ND1, subunits of mitochondrial complex I, maintaining its activity and preventing oxidative damage to the electron transport chain (Hayashi et al., 2009).
- Mitochondrial dynamics: DJ-1 loss leads to mitochondrial fragmentation and impaired fusion-fission balance, phenotypically overlapping with [PINK1[/genes/[pink1[/genes/[pink1[/genes/[pink1--TEMP--/genes)--FIX-- and [Parkin[/genes/[prkn[/genes/[prkn[/genes/[prkn--TEMP--/genes)--FIX-- deficiency.
- Membrane potential: Products of DJ-1's glyoxalase activity (D-lactate and glycolate) directly support mitochondrial membrane potential and neuronal survival.
DJ-1 regulates dopamine biosynthesis and signaling through multiple mechanisms:
- Tyrosine hydroxylase regulation: DJ-1 modulates the activity of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.
- [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- receptor signaling: DJ-1 interacts with the dopamine D2 receptor and modulates downstream signaling cascades.
- Dopamine transporter: DJ-1 influences dopamine reuptake through regulation of dopamine transporter (DAT) expression and membrane localization.
DJ-1 possesses molecular chaperone activity, preventing aggregation of [α-synuclein/proteins/alpha and other proteins prone to misfolding. This function is dependent on oxidation of C106 and is enhanced under mild oxidative stress conditions (Shendelman et al., 2004) (Shendelman et al., 2004).
DJ-1 in [microglia[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/[astrocytes[/astrocytes, DJ-1 suppresses inflammatory mediator production by regulating [STAT1[/genes/[stat1[/genes/[stat1[/genes/[stat1--TEMP--/genes)--FIX-- signaling.
- In [microglia, DJ-1 deficiency enhances pro-inflammatory cytokine release and [NLRP3[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome[/mechanisms/[nlrp3-inflammasome--TEMP--/mechanisms)--FIX-- inflammasome] activation (Kim et al., 2023)).
- A 2025 study identified a novel role for DJ-1 in regulating intercellular communication via [extracellular vesicles[/mechanisms/[extracellular-vesicles[/mechanisms/[extracellular-vesicles[/mechanisms/[extracellular-vesicles--TEMP--/mechanisms)--FIX-- under oxidative stress (Singh et al., 2025), highlighting DJ-1's function in cell-to-cell signaling during neurodegeneration.
¶ Genetics and Disease-Causing Mutations
Over 20 pathogenic mutations in PARK7 have been identified, including point mutations, deletions, and splicing variants (Bonifati et al., 2003):
| Mutation |
Effect |
Clinical Phenotype |
| L166P |
Destabilizes dimer; rapid proteasomal degradation |
Early-onset PD, slow progression |
| M26I |
Reduced stability; impaired oxidative stress response |
Early-onset PD |
| E64D |
Reduced glyoxalase activity |
Early-onset PD |
| A104T |
Impaired dimerization |
Early-onset PD |
| D149A |
Loss of catalytic activity |
Early-onset PD |
| Exon 1–5 deletion |
Complete loss of protein |
Early-onset PD |
The PARK7-linked PD phenotype is characterized by:
- Early onset (typically 20–40 years of age)
- Slowly progressive parkinsonism
- Good and sustained response to [levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX-- therapy
- Occasional psychiatric features (anxiety, psychotic features)
- [Dystonia[/diseases/[dystonia[/diseases/[dystonia[/diseases/[dystonia--TEMP--/diseases)--FIX-- may be present at onset
- Asymmetric onset with tremor, rigidity, and bradykinesia
DJ-1 functionally converges with the [PINK1[/genes/[pink1[/genes/[pink1[/genes/[pink1--TEMP--/genes)--FIX--–[Parkin[/genes/[prkn[/genes/[prkn[/genes/[prkn--TEMP--/genes)--FIX-- [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- pathway, though it operates through a parallel mechanism:
- All three proteins (DJ-1, [PINK1[/proteins/[pink1-protein[/proteins/[pink1-protein[/proteins/[pink1-protein--TEMP--/proteins)--FIX--, Parkin) are linked to autosomal recessive early-onset PD.
- Loss of DJ-1, like PINK1 and Parkin deficiency, causes [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, increased [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, and dopaminergic neuron vulnerability.
- DJ-1 overexpression can rescue PINK1 deficiency phenotypes in Drosophila models, but not vice versa, placing DJ-1 downstream or in parallel to the PINK1-Parkin axis (Hao et al., 2010).
- DJ-1 and Parkin may physically interact, and DJ-1 stabilizes Parkin in the cytoplasm under oxidative stress.
Oxidized DJ-1 (DJ-1-SO₂H) in blood and cerebrospinal fluid has been proposed as a biomarker for PD. Changes in DJ-1 oxidation state may correlate with disease progression and oxidative stress burden, though standardization of assays remains a challenge (Saito et al., 2014).
- Small molecules that stabilize DJ-1 or prevent its over-oxidation are under preclinical investigation. UCP0045037, an allosteric modulator of the reduced form of DJ-1, has shown neuroprotective effects in oxidative neurodegeneration models (Miyazaki et al., 2020).
- Gene therapy approaches to restore DJ-1 expression in dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are in early development.
- Nrf2 activators (which mimic DJ-1's transcriptional effects) are in [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials for neurodegenerative diseases.
- Glyoxalase pathway modulation may offer protection against glycation-mediated neuronal damage.
- [Mitochondrial] targeting strategies that compensate for DJ-1 loss are being explored.
- [Parkin[/proteins/[parkin[/proteins/[parkin[/proteins/[parkin--TEMP--/proteins)--FIX--
The study of Dj 1 (Park7) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA. (2003). The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Proc Natl Acad Sci USA 100(16):9256-61. PubMed)
- [Honbou K, et al. (2003). The crystal structure of DJ-1, a protein related to male fertility and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. J Biol Chem 278(33):31380-4. PubMed)
- [Canet-Avilés RM, et al. (2004). The [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101(24):9103-8. PubMed)
- [Olzmann JA, et al. (2004). Familial Parkinson's Disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 279(9):8506-15. PubMed)
- [Taira T, et al. (2004). DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5(2):213-8. PubMed)
- [Clements CM, et al. (2006). DJ-1, a cancer- and Parkinson's Disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103(41):15091-6. PubMed)
- [Lockhart PJ, et al. (2004). DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 41(3):e22. PubMed)
- [Lee JY, et al. (2012). Human DJ-1 and its homologs are novel glyoxalases. Hum Mol Genet 21(14):3215-25. PubMed)
- [Shendelman S, et al. (2004). DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol 2(11):e362. PubMed)
- [Hayashi T, et al. (2009). DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun 390(3):667-72. PubMed)
- [Hao LY, Giasson BI, Bhatt NB. (2010). DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc Natl Acad Sci USA 107(21):9747-52. PubMed)
- [Kim J, et al. (2023). PARK7/DJ-1 in [microglia: implications in Parkinson's Disease and relevance as a therapeutic target. J [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- 20(1):55. PubMed)
- [Singh K, et al. (2025). Parkinson's associated protein DJ-1 regulates intercellular communication via extracellular vesicles in oxidative stress. Cell Death Discovery 11:53. . . DOI
- [Andreeva A, et al. (2024). DJ-1 protects proteins from acylation by catalyzing the hydrolysis of highly reactive cyclic 3-phosphoglyceric anhydride. Nature Communications 15:2404. . . DOI
- [Pfaff DH, et al. (2024). PARK7 Catalyzes Stereospecific Detoxification of Methylglyoxal Consistent with Glyoxalase and Not Deglycase Function. Biochemistry 63(1):21-33. PubMed)